NASDAQ:LPTXLeap Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Leap Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.37 +0.14 (+6.28 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$2.20Now: $2.37▼$2.4850-Day Range$1.61MA: $2.08▼$2.4052-Week Range$0.57Now: $2.37▼$3.18Volume648,963 shsAverage Volume656,234 shsMarket Capitalization$84.84 millionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingLeap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Leap Therapeutics has a potential upside of 89.9% from its current price of $2.37.Amount of Analyst CoverageLeap Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesLeap Therapeutics has received 252 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLeap Therapeutics has received 236 “underperform” votes. (Add your “underperform” vote.)Community SentimentLeap Therapeutics has received 51.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote “Outperform” if you believe LPTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 25.89% of the stock of Leap Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 31.38% of the stock of Leap Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Leap Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 4.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPTX Previous Symbol CUSIPN/A CIK1509745 Webwww.leaptx.com Phone617-714-0360Debt Debt-to-Equity Ratio0.03 Current Ratio2.82 Quick Ratio2.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book4.74Profitability EPS (Most Recent Fiscal Year)($1.47) Net Income$-32,900,000.00 Net MarginsN/A Return on Equity-385.48% Return on Assets-178.96%Miscellaneous Employees23 Outstanding Shares35,799,000Market Cap$84.84 million Next Earnings Date8/14/2020 (Estimated) OptionableNot Optionable NASDAQ:LPTX Rates by TradingView Receive LPTX News and Ratings via Email Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions How has Leap Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LPTX stock has increased by 17.9% and is now trading at $2.37. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Leap Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Leap Therapeutics. When is Leap Therapeutics' next earnings date? Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Leap Therapeutics. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics Inc (NASDAQ:LPTX) posted its earnings results on Thursday, May, 14th. The company reported ($0.55) EPS for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.31. The firm earned $0.38 million during the quarter. View Leap Therapeutics' earnings history. What price target have analysts set for LPTX? 3 brokers have issued 1 year price objectives for Leap Therapeutics' shares. Their forecasts range from $2.50 to $6.00. On average, they anticipate Leap Therapeutics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View analysts' price targets for Leap Therapeutics. Has Leap Therapeutics been receiving favorable news coverage? News stories about LPTX stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Leap Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutLeap Therapeutics. Are investors shorting Leap Therapeutics? Leap Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,430,000 shares, an increase of 32.4% from the April 30th total of 1,080,000 shares. Based on an average trading volume of 436,600 shares, the short-interest ratio is presently 3.3 days. Approximately 6.7% of the shares of the company are sold short. View Leap Therapeutics' Current Options Chain. Who are some of Leap Therapeutics' key competitors? Some companies that are related to Leap Therapeutics include Avid Bioservices (CDMO), TherapeuticsMD (TXMD), Lannett (LCI), OrganiGram (OGI), Osmotica Pharmaceuticals (OSMT), Avadel Pharmaceuticals (AVDL), Concert Pharmaceuticals (CNCE), Evofem Biosciences (EVFM), Ovid Therapeutics (OVID), Bicycle Therapeutics (BCYC), Verastem (VSTM), Urovant Sciences (UROV), AMAG Pharmaceuticals (AMAG), Neptune Wellness Solutions (NEPT) and Agile Therapeutics (AGRX). View all competitors. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Amarin (AMRN), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), Verastem (VSTM), Clearside Biomedical (CLSD), Genocea Biosciences (GNCA) and ImmunoGen (IMGN). Who are Leap Therapeutics' key executives? Leap Therapeutics' management team includes the following people: Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63) What is Leap Therapeutics' stock symbol? Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX." Who are Leap Therapeutics' major shareholders? Leap Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (18.79%), Perceptive Advisors LLC (18.79%), Sphera Funds Management LTD. (1.68%), Personal CFO Solutions LLC (0.18%), BlackRock Inc. (0.11%) and MYDA Advisors LLC (0.08%). View institutional ownership trends for Leap Therapeutics. Which major investors are buying Leap Therapeutics stock? LPTX stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Sphera Funds Management LTD., Personal CFO Solutions LLC, MYDA Advisors LLC, Gratus Capital LLC, and BlackRock Inc.. View insider buying and selling activity for Leap Therapeutics. How do I buy shares of Leap Therapeutics? Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Leap Therapeutics' stock price today? One share of LPTX stock can currently be purchased for approximately $2.37. How big of a company is Leap Therapeutics? Leap Therapeutics has a market capitalization of $84.84 million. The company earns $-32,900,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe. What is Leap Therapeutics' official website? The official website for Leap Therapeutics is www.leaptx.com. How can I contact Leap Therapeutics? Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360. This page was last updated on 5/29/2020 by MarketBeat.com Staff
